Sai Parenterals has secured INR 50 crore in equity funding from marquee investors including Samarsh Capital, Vyom Partners, and funds affiliated with Blue Lotus Capital. The capital will fuel the company’s global expansion strategy and strengthen its capabilities across the pharmaceutical value chain.

Anil Karusala, Managing Director of Sai Parenterals, stated, “We are committed to building a world-class pharmaceutical company that adheres to global standards. This infusion will support acquisitions in regulated markets, portfolio expansion, and enhanced manufacturing capabilities.”

Sandeep Shenoy, Managing Partner at Samarsh Capital, said the investment reflects their confidence in Sai Parenterals’ fundamentals and potential for global leadership.

Prashant Khanchandani of Vyom Partners praised the company’s capital-efficient and scalable approach, especially in integrating acquisitions and growing internationally in the formulations and CDMO space.

Harikrishnan S of Blue Lotus Capital added, “This second round of investment underlines our belief in Sai Parenterals’ science-driven model and scalable sterile injectables platform.”

Sai Parenterals operates across research and development, manufacturing, compliance, marketing, and exports. The company is well-positioned to deliver affordable, high-quality healthcare globally and create long-term value for stakeholders through its expanding international footprint.